Simon Kung, MD

Department of Psychiatry and Psychology, Mayo Clinic, Rochester, Minnesota.

  • 9Articles
  • 49KReads
  • 2011–2026Active
  • 54Collaborators
  • 137Citations

About

Simon Kung, MD, is affiliated with the Department of Psychiatry and Psychology at the Mayo Clinic in Rochester, Minnesota. Dr. Kung has published extensively on treatment-resistant depression, bipolar disorder, and the use of ketamine and esketamine in depressive disorders. His work also encompasses genetic factors in antidepressant response, suicide risk, and stress management interventions in major depressive disorder. His research contributions span from 2011 to 2026 in peer-reviewed journals including Psychiatrist.com.

Publications

JCP
Next-Step Treatment Options for Treatment-Resistant Depression
Consensus Statement

Next-Step Treatment Options for Treatment-Resistant Depression

January 21, 2026

Strong consensus emerged for augmentation with second-generation antipsychotics, TMS, and ketamine/esketamine in the base vignette. Preferences shifted to include non-augmentative antidepressants and ECT based on patient characteristics.
, , , et al
JCP
Ketamine Reduces Suicidality Associated ED Use in Patients With Treatment-Resistant Depression
Original Research

Ketamine Reduces Suicidality Associated ED Use in Patients With Treatment-Resistant Depression

September 17, 2025

After the acute phase of ketamine treatment, ED visits for suicidal ideation decreased by 84%, and total ED visits for suicidality decreased by 63%.
, , , et al
JCP
Long-Term Outcomes of IV Ketamine and IN Esketamine in Treatment-Refractory Depression
Original Research

Long-Term Outcomes of IV Ketamine and IN Esketamine in Treatment-Refractory Depression

July 30, 2025

The study results suggest that patients with treatment-resistant depression who are on maintenance treatment require less frequent treatments with IV ketamine compared to IN esketamine.
, , , et al
JCP
Pilot Study of High Frequency TMS for Bipolar Depression
Original Research

Pilot Study of High Frequency TMS for Bipolar Depression

May 20, 2024

In this study of patients with bipolar depression, 87.1% reached response and 74.2% reached remission with 6 weeks of rTMS.
, , , et al
JCP
Ketamine vs Esketamine for TRD
Original Research

Ketamine vs Esketamine for TRD

February 1, 2023

Are ketamine and esketamine equally efficacious? This observational study compares the efficacy of subanesthetic intravenous ketamine with that of intranasal esketamine for treatment-resistant depression in a real-world clinical setting.
, , , et al
PCC
Original Research

Stress Management and Resiliency Training for Depression

April 30, 2020

Stress is associated with the onset, maintenance, and recurrence of depression. This study aimed to investigate the feasibility of stress management and resiliency training for enhancing resiliency in a...
, , , et al
JCP
Original Research

Clinical Risk Factors and Serotonin Transporter Gene Variants Associated With Antidepressant-Induced Mania

January 6, 2015

, , , et al
JCP
Original Research

Code Status Discussions in Psychiatric and Medical Inpatients

November 25, 2014

, , , et al
JCP
Letter to the Editor

Patients and Clinicians Report Higher-Than-Average Satisfaction With Psychiatric Genotyping for Depressed Inpatients

February 15, 2011

,

Physicians Postgraduate Press, Inc. (PPP) makes no warranties about the accuracy or completeness of any information published in The Journal of Clinical Psychiatry or other PPP materials, and disclaims liability for any use or non-use of that information. Clinicians should not rely solely on these materials and should exercise their own professional judgment when making patient care decisions on an individualized basis.

Learn More About Psychedelics in Psychiatry

Explore the Collection
Neural network illustration symbolizing psychedelic research advancements

Subscribe to read
more articles

Subscribe